Amarin Corporation plc
NASDAQ:AMRNBiotechnology
+$0.29 today
- Market cap
- $232.89M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
Volume 0.09M
Average 0.07M
AMRN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Amarin Corporation plcNASDAQ: AMRN
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$11.66M, compared with -$12.9M a year earlier. Trailing-twelve-month EBITDA was -$5.14M.
Context
- EBITDA amounted to 15.5% of revenue in FY2025, down 17.0 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of -$20.97M (+36.5%) for the fiscal year ending Dec 2026, a slowdown from the +55.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$11.66M-7686.5% QoQ
- Last fiscal yearDec 2025
- -$33.01M+55.5% YoY
- LTMMar 2026
- -$5.14M+92.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.6% | -94.3% | -103.9 pp |
| 1 year | +55.5% | +36.5% | -19.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (33.01M) USD
- Year-over-year change
- +55.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.01M) | +55.5% |
| FY2024 | 2024-12-31 | (74.18M) | -46.3% |
| FY2023 | 2023-12-31 | (50.7M) | +49.7% |
| FY2022 | 2022-12-31 | (100.69M) | -805.4% |
| FY2021 | 2021-12-31 | 14.28M | — |
EBITDA vs competitors
How AMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +92.4% is the highest of 10, against a peer median of -29.6%.
- EBITDA amounts to 2.4% of revenue for AMRN, versus a peer median of 5256.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$5.14M USD | +92.4% | — | 2.4% | |
| LTM Mar 2026 | -$51.11M USD | -57.3% | — | 75.1% | |
| LTM Mar 2026 | -CHF 64.45M CHF | -29.6% | — | 1740.8% | |
| LTM Mar 2026 | -$71.29M USD | -16.9% | — | — | |
| LTM Mar 2026 | -$78.13M USD | — | — | 8478.5% | |
| LTM Mar 2026 | -$78.15M USD | +14.5% | — | 2034.0% | |
| LTM Mar 2026 | -$88.27M USD | +2.7% | — | 245200.0% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$125.94M USD | -65.1% | — | — |
| LTM Mar 2026 | -$159.48M USD | -49.1% | — | — | |
| LTM Mar 2026 | -$165.68M USD | -74.6% | — | — | |
| LTM Mar 2026 | -$238.99M USD | -27.7% | — | 770932.3% | |
| Peer median (excluding AMRN) | — | -29.6% | — | 5256.3% | |
Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 583.19M | 369.19M | 306.91M | 228.61M | 213.65M |
| Cost of Revenue | 121.33M | 126.71M | 141.37M | 147.23M | 92.78M |
| Gross Profit | 461.86M | 242.48M | 165.54M | 81.38M | 120.87M |
| Gross Margin | 79.2% | 65.7% | 53.9% | 35.6% | 56.6% |
| Research & Development | 29.31M | 30.41M | 22.22M | 20.87M | 19.81M |
| Selling, General & Admin | 408.33M | 304.42M | 199.94M | 152.31M | 115M |
| Operating Expenses | 451.36M | 348.35M | 222.16M | 173.18M | 134.81M |
| Depreciation & Amortization | 2.86M | 3.1M | 2.97M | 3.01M | 3.03M |
| EBITDA | 14.28M | (100.69M) | (50.7M) | (74.18M) | (33.01M) |
| EBITDA Margin | 2.4% | -27.3% | -16.5% | -32.4% | -15.5% |
| Operating Income | 10.5M | (105.87M) | (56.62M) | (91.8M) | (13.94M) |
| Operating Margin | 1.8% | -28.7% | -18.4% | -40.2% | -6.5% |
| Interest Income | 1.22M | 2.82M | 11.86M | 13.4M | 10.85M |
| Interest Expense | 129K | 15K | 8K | 7K | 7K |
| Other Income / Expenses | 789K | 2.06M | 2.95M | 14.6M | (22.11M) |
| Income Before Tax | 11.29M | (103.81M) | (53.67M) | (77.2M) | (36.05M) |
| Pre-Tax Margin | 1.9% | -28.1% | -17.5% | -33.8% | -16.9% |
| Income Tax Expense | 3.56M | 2M | 5.44M | 4.98M | 2.75M |
| Net Income | 7.73M | (105.8M) | (59.11M) | (82.18M) | (38.8M) |
| Net Margin | 1.3% | -28.7% | -19.3% | -35.9% | -18.2% |
| EPS (Basic) | 0.39 | (5.20) | (3.00) | (4.00) | (1.80) |
| EPS (Diluted) | 0.38 | (5.20) | (3.00) | (4.00) | (1.80) |
| Weighted Avg Shares | 19.8M | 20.06M | 19.7M | 20.55M | 20.75M |
| Weighted Avg Shares (Diluted) | 20.12M | 20.06M | 20.38M | 20.55M | 20.75M |
Amarin Corporation plc
NASDAQ:AMRN
Intrinsic Alpha fair value
Locked
Current Price
$11.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.